KOD logo

KOD Kodiak Sciences Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$97.17
-0.73 (-0.75%)

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, tar…

Market Cap: $6.35Bkodiak.com

Price

No data yet.

Social Signal Score

51
5d
—
30d
53
4 mentions
—
60d
50
16 mentions
—
90d
50
16 mentions
—
news: 11 · 4chan: 2 · marketaux: 1 · rss: 2

Analyst Ratings

19 analysts
Buyconsensus
Strong Buy 0Buy 14Hold 4Sell 1Strong Sell 0
Avg price target$115.25+18.6%
Low $103Median $116High $126
Current Consensus

Revenue

$0.00
$0.00
Mar 2017Sep 2026

Analyst Estimates

FY2025
$-4.27
$-4.51–$-3.63
5 analysts
FY2026
$-4.04
$-4.18–$-3.89
4 analysts
FY2027
$-3.76
$-4.38–$-3.13
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Victor Perlroth
Sector
Healthcare
Industry
Biotechnology
Employees
144
Beta
1.98
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
4.05
kodiak.com